Ascendis Pharma A/S (ASND) vs Genmab A/S (GMAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genmab A/S (GMAB) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 10.1% versus a gain of 6.0%. Over five years, ASND leads with a +39.2% price change compared with -18.9% for GMAB. Genmab A/S is the larger company by market cap ($22.82 billion vs $15.04 billion), about 1.5 times the size.
On valuation, Ascendis Pharma A/S trades at a lower forward P/E (21.2x vs 24.3x for Genmab A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | GMAB |
|---|---|---|
| Share price | $228.61 | $37.12 |
| Market cap | $15.04B | $22.82B |
| 1-day change | +2.66% | +2.95% |
| YTD return | +4.43% | +17.05% |
| 1-year return | +5.98% | +10.11% |
| 5-year return | +39.19% | -18.86% |
| P/E ratio (TTM) | 17.52 | 29.22 |
| Forward P/E | 21.22 | 24.34 |
| EPS (TTM) | $13.05 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.72B |
| Revenue growth (YoY) | — | +19.19% |
| Net income (latest FY) | — | $963.00M |
| Gross margin | — | 93.60% |
| Operating margin | — | 28.63% |
| Net margin | — | 25.89% |
| 52-week high | $282.15 | $40.17 |
| 52-week low | $186.05 | $23.62 |
| Distance from 52-week high | -18.98% | -7.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +33.78% | +16.45% |
| Average volume | 662.79K | 2.83M |
| Shares outstanding | 65.80M | 614.90M |
| Employees | 1,189 | 3,119 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S trades at a higher earnings multiple (29.2x vs 17.5x trailing P/E).
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
ASND vs GMAB FAQ
Which is bigger, Ascendis Pharma A/S or Genmab A/S?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.82B compared with $15.04B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ASND or GMAB?
GMAB returned +10.11% over the past 12 months, compared with +5.98% for ASND (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or GMAB?
ASND has the lower trailing P/E at 17.5, versus 29.2 for GMAB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ascendis Pharma A/S and Genmab A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.